Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Substance Withdrawal Clear all
Completed Phase 2 Interventional Results available

Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients

NCT02913924
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Clonazepam, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

NCT01618656
View directory record Official record
Conditions
Cannabis Dependence
Interventions
PF-04457845, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 21, 2026, 3:44 AM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 21, 2026, 3:44 AM EDT
Withdrawn Phase 1Phase 2 Interventional

GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1

NCT00123578
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Lorazepam, Pentobarbital
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 4 Interventional Results available

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

NCT04298853
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
Interventions
Morphine PRN, Morphine scheduled
Drug
Lead sponsor
Indiana University
Other
Eligibility
Up to 28 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 21, 2026, 3:44 AM EDT
Terminated Phase 3 Interventional

Study of Probuphine in Patients With Opioid Dependence

NCT00772785
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Early Phase 1 Interventional Results available

Progesterone for Cannabis Withdrawal

NCT03430050
View directory record Official record
Conditions
Cannabis Use Disorder, Cannabis Withdrawal
Interventions
Progesterone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 21, 2026, 3:44 AM EDT
Active, not recruiting Not applicable Interventional Results available

NET Device for Treating Opioid Use Disorder

NCT04916600
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NET
Device
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Willisburg, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 21, 2026, 3:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

Overcoming Nicotine Dependence to Enable Quitting

NCT05513872
View directory record Official record
Conditions
Tobacco Use, Smoking Cessation, Smoking Behaviors, Nicotine Dependence, Nicotine Withdrawal
Interventions
Nicotine Replacement Therapy (NRT) Sampling, Practice Quitting (PQ) Counseling, Motivational Interviewing (MI) Counseling
Drug · Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

NCT04731935
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal
Interventions
Sparrow Therapy System
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 21, 2026, 3:44 AM EDT
Completed No phase listed Observational

AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)

NCT04422808
View directory record Official record
Conditions
Withdrawal Syndrome, Iatrogenic Disease
Interventions
Not listed
Lead sponsor
Wilkes University
Other
Eligibility
18 Years and older
Enrollment
2,437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 3 Interventional Results available

Improving Outcomes in Neonatal Abstinence Syndrome

NCT01958476
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Interventions
Neonatal Morphine Solution, Methadone, Phenobarbital
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Jacksonville, Florida • Portland, Maine • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 2 Interventional

Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome

NCT00510016
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine HCL
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
Up to 14 Days
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 2 Interventional

Effects of Dynorphin 1-13 on Heroin Addiction - 1

NCT00000244
View directory record Official record
Conditions
Opioid-Related Disorders, Substance Withdrawal Syndrome
Interventions
Dynorphin 1 - 13
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1997
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing an Arts-based Program to Reduce Nurse Stigma Towards Perinatal Substance Use

NCT06410287
View directory record Official record
Conditions
Nurse's Role, Stigma, Social, Implicit Bias
Interventions
ArtSpective
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Saint Cloud, Minnesota • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 3:44 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Anxiety During Abstinence in AUD

NCT06793488
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Disulfiram 250 mg, functional MRI
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders

NCT02232737
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Very low nicotine content cigarettes
Other
Lead sponsor
Brown University
Other
Eligibility
18 Years to 70 Years
Enrollment
775 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Providence, Rhode Island • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 21, 2026, 3:44 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt

NCT00571805
View directory record Official record
Conditions
Nicotine Dependence
Interventions
varencline, placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 1 Interventional

Antagonist-Elicited Cannabis Withdrawal

NCT01041170
View directory record Official record
Conditions
Cannabis, Dependence
Interventions
THC, Rimonobant, Rimonabant
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 1 Interventional

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3

NCT00000354
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Lofexidine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 3 Interventional

Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 21, 2026, 3:44 AM EDT
Completed No phase listed Observational Results available

Donor Human Milk in Neonatal Abstinence Syndrome

NCT02182973
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
donor human milk
Dietary Supplement
Lead sponsor
Neolac Inc dba Medolac Laboratories
Industry
Eligibility
38 Weeks to 42 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Not applicable Interventional

A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)

NCT00001008
View directory record Official record
Conditions
HIV Infections
Interventions
Methadone hydrochloride, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 21, 2026, 3:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

NCT01137890
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Zonisamide, Placebo, Cocaine Hydrochloride, Neurocognitive and Performance Battery, Smoking Assessments
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 21, 2026, 3:44 AM EDT